10x Genomics (TXG) Other Accumulated Expenses (2018 - 2026)

10x Genomics has disclosed Other Accumulated Expenses across 9 years of filings, most recently posting $8.4 million for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $8.4 million, down 31.42% year-over-year; the trailing twelve-month figure through Mar 2026 was $8.4 million (down 31.42% YoY), and the FY2025 annual result was $11.0 million, changed N/A from the prior year.
• Other Accumulated Expenses came in at $8.4 million for Q1 2026 at 10x Genomics, down from $11.0 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $12.8 million in Q2 2025 to a low of $3.3 million in Q2 2023.
• The 5-year median for Other Accumulated Expenses is $6.0 million (2022), against an average of $7.3 million.
• Peak annual rise in Other Accumulated Expenses reached 657.19% in 2022, while the deepest fall reached 83.31% in 2022.
• 10x Genomics' Other Accumulated Expenses stood at $6.7 million in 2022, then sank by 34.2% to $4.4 million in 2023, then increased by 29.59% to $5.7 million in 2024, then jumped by 92.25% to $11.0 million in 2025, then fell by 23.28% to $8.4 million in 2026.
• The last three Other Accumulated Expenses figures came in at $8.4 million (Q1 2026), $11.0 million (Q4 2025), and $12.4 million (Q3 2025), per Business Quant data.